Meghan Markle is making deeper moves into the startup world, stepping up as an angel investor in Midi Health. A fast-growing virtual care platform focused on women’s health, particularly menopause-related care.
In a recent interview with Fortune, Meghan confirmed her involvement in Midi’s mission to transform how women receive healthcare during pivotal life stages. According to sources close to the matter, she joined the company’s $63 million Series B funding round in March. Marking one of her most prominent health tech investments to date.
The funding round also drew attention with backing from high-profile investors including Laurene Powell Jobs’ Emerson Collective, designer and entrepreneur Tory Burch, and VC firm G9 Ventures, as reported by PitchBook. Midi’s platform delivers personalized care for women navigating perimenopause, menopause, and other midlife health transitions. An area historically underserved by traditional healthcare systems.
Meghan’s investment in Midi isn’t a one-off. Since relocating to the U.S. five years ago, she’s quietly built an angel portfolio of more than 10 startups. Backing ventures in sectors like consumer goods, fintech, edtech, and wellness. According to a source familiar with her investment activity, she prioritizes companies that have at least one female founder.
Her portfolio already includes Clevr Blends, a woman-led beverage brand offering superfood lattes, and Highbrow Hippie. A wellness and lifestyle startup with a strong focus on conscious living. These investments reflect her broader mission to support innovation that uplifts women and addresses overlooked markets.
Meghan’s increasing involvement in angel investing aligns with a growing trend of celebrities and public figures using their platforms—and capital—to support purpose-driven startups. With Midi Health, she’s putting a spotlight on menopause care. A space long ignored by venture capital and traditional medicine despite the fact that nearly half the population will go through it.
Midi Health aims to change that narrative, offering virtual consultations, treatment plans. And ongoing care tailored to women’s unique hormonal needs. The startup’s Series B raise will be used to expand its clinical offerings. Enhance its tech infrastructure, and grow its provider network across the U.S.
Meghan’s role as a backer not only adds star power but signals growing investor interest in women’s health and femtech more broadly. Her involvement may also help normalize conversations around menopause and reproductive health. Driving awareness and encouraging other investors to take notice.
As Meghan continues to carve out her path in business, her strategy is becoming clearer: support early to mid-stage companies tackling real problems, led by women, and built with purpose.
